Key result
Aspirin reduced the risk of recurrent VTE and VTE-related death compared to placebo (6.3% vs 11.0% patient-years; HR 0.57, 95% CI 0.35-0.93) after 6-12 months of oral anticoagulation.
Why the study?
Does aspirin 100 mg daily reduce the composite of recurrent symptomatic VTE and VTE-related death in patients with a first-ever unprovoked VTE who have completed 6-12 months of oral anticoagulation?
Population
402 patients with a first-ever unprovoked VTE who had completed 6–12 months of oral anticoagulant treatment.
Comparison
Aspirin 100 mg daily for at least two years. vs Placebo for at least two years.
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
mean 24 months
Authors
Loading...
Supports aspirin for extended secondary prevention in unprovoked VTE; confirms benefit versus placebo after standard anticoagulation.
RCT (n=402)
double-blind
randomized
Does aspirin 100 mg daily reduce the composite of recurrent symptomatic VTE and VTE-related death in patients with a first-ever unprovoked VTE who have completed 6-12 months of oral anticoagulation?
Hazard Ratio: 0.57 (95% CI 0.35–0.93)
Absolute Event Rate: 6.3% vs 11%
Aspirin is a safe and effective alternative for extended secondary prevention of unprovoked VTE after completing a standard 6-12 month course of oral anticoagulation.
Becattini et al. (2011) conducted an RCT in unprovoked venous thromboembolism (VTE) (n=402). Aspirin vs. Placebo was evaluated on objectively confirmed recurrent symptomatic VTE and VTE-related death (HR 0.57, 95% CI 0.35 to 0.93). Aspirin reduced the risk of recurrent VTE and VTE-related death compared to placebo (6.3% vs 11.0% patient-years; HR 0.57, 95% CI 0.35-0.93) after 6-12 months of oral anticoagulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: